[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pneumococcal-immunization\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pneumococcal-immunization":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100619751","phase-3-lot-to-lot-consistency-study-of-a-21-valent-pneumococcal-conjugate-vaccine-in-healthy-infants-from-2-months-of-age-100619751",false,"NCT07348692","Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age","A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, Lot-to-lot Consistency, 4-arm Study to Investigate the Safety and Immunogenicity of a 4-dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers","Inclusion Criteria:\n\n* Aged 42 to 89 days on the day of inclusion\n* Participants who are healthy as determined by medical evaluation including medical history and physical examination\n* Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg or born after a gestation period above 28 (\\> 28 weeks) through 36 weeks with a birth weight ≥ 1.5 kg, and in both cases medically stable\n\nExclusion Criteria:\n\n* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy; or long-term systemic corticosteroid therapy\n* History of microbiologically confirmed Streptococcus pneumoniae infection or disease\n* Any contraindication to the routine pediatric vaccine being administered in the study\n* History of seizure or significant stable or progressive neurologic disorders such as infantile spasms, inflammatory nervous system diseases, encephalopathy, cerebral palsy\n* Known systemic hypersensitivity to any of the study interventions components, or history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances3\n* Laboratory-confirmed or known thrombocytopenia, as reported by the parent(s) \u002F legally acceptable representative (LAR(s)), contraindicating intramuscular (IM) injection.\n* Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM injection.\n* Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion\n* Moderate or severe acute illness\u002Finfection (according to investigator judgment) or febrile illness (temperature ≥ 38.0°C \\[≥ 100.4°F\\]) on the day of study intervention administration.\n* Receipt of any BCG vaccine within 4 weeks preceding the first study intervention administration or planned receipt any BCG vaccine within the study period\n* Previous vaccination against Streptococcus pneumoniae\n* Previous vaccination against the following antigens: diphtheria, tetanus, pertussis, H. influenzae type b, poliovirus\n* Receipt of more than 1 dose of hepatitis B vaccine\n* Receipt of immune globulins, blood or blood-derived products since birth\n* Participation at the time of study enrollment (or in the 6 weeks preceding the first study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure\n\nNote: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.",true,"ALL","42 Days","89 Days",{"count":21,"type":22},2195,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This is a phase 3 randomized, modified double-blind study whose purpose is to measure whether 3 lots of the investigational pneumococcal vaccine PCV21 can help the body to develop germ-fighting agents called \"antibodies\" (immunogenicity) in a similar way (ie, same immune response) when they are given to infants aged from approximately 2 months (42 to 89 days) and are safe compared to a licensed 20-valent pneumococcal vaccine (20vPCV) (Prevnar 20™).\n\nThe study duration per participant will be up to approximately 17 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 months of age. Cohort A will include randomization to three PCV21 formulation groups or one 20vPCV comparator group (Group 1-4, approximately 896 total participants), whereas Cohort B will include randomization to three PCV21 formulation groups only (Groups 1-3, approximately 1299 total participants). Routine pediatric vaccines will be given as per local recommendations.\n\nThere will be 6 study visits: Visit (V)01, V02 separated from V01 by 60 days, V03 separated from V02 by 60 days, V04 separated from V03 by 30 days, V05 at 12 months of age, V06 separated from V05 by 30 days",[28,29],"Pneumococcal Immunization","Healthy Volunteers",[31,32],"Pneumococcal Infection","21 Valent Pneumococcal Vaccine","RECRUITING","2026-05-21",{"date":36,"type":37},"2026-05-22","ACTUAL",{"date":39,"type":37},"2026-01-20",{"date":41,"type":22},"2028-05-29",{"name":43,"class":44},"Sanofi","INDUSTRY",19,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100574509","a-study-to-learn-more-about-prevenar-20-once-it-is-out-in-the-korean-market-100574509","NCT06760208","A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market","Korean Post-marketing Surveillance for Prevenar 20","Inclusion Criteria:\n\nSubjects must meet all of the following inclusion criteria to be eligible for inclusion in the study:\n\n1. Infant, children and adolescents who are aged 6 weeks to under 18 years or adult who are 18 years or older\n2. Subjects who have been prescribed Prevenar 20 by their physician as per approved product label\n3. Evidence of a personally signed and dated informed consent document indicating that the subject or their parent(s)\u002Flegal guardian, if applicable, have been informed of all pertinent aspects of the study\n\nExclusion Criteria:\n\nSubjects meeting any of the following criteria will not be included in the study:\n\n1. Subjects with contraindication according to approved label of Prevernar 20 (Pneumococcal 20-valent conjugate vaccine)\n2. Any subjects (or a legally acceptable representative) who do not agree that Pfizer and companies working with Pfizer use his\u002Fher information","6 Weeks",{"count":55,"type":22},660,"OBSERVATIONAL","The purpose of this study is to understand the safety of Prevenar 20 (Pneumococcal 20-valent conjugate vaccine) once it is out in the Korean market. Prevenar 20 will be given to participants aged 6 weeks or older in Republic of Korea.\n\nThis study is seeking for participants who are:\n\n* Infant, children and adolescents aged 6 weeks to under 18 years or adult who are 18 years or older\n* Prescribed Prevenar 20 by their physician as per approved product label\n\nAll participants in this study will receive Prevenar 20 vaccine.\n\n1 dose (0.5 mL) of Prevenar 20 will be given into a muscle, preferably to the shoulder muscle.\n\nWe will look at the experiences of people receiving the study medicine. This will help us see if the study medicine is safe.\n\nParticipants will take part in this study for 28 days. During this time, study doctor collects the data of subjects to understand the safety of study medicine. There is no strict fixed visit schedule. If subjects are unable to visit the study clinic 28 days after Prevenar 20 vaccine was given then the safety information will be collected by telephone or e-mail.",[28,59],"Safety","2026-03-10",{"date":62,"type":37},"2026-03-12",{"date":64,"type":37},"2025-11-13",{"date":66,"type":22},"2027-03-01",{"name":68,"class":44},"Pfizer",1]